Advertisements

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA.....»»

Category: topSource: moneycontrolDec 2nd, 2019

Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia

Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia.....»»

Category: topSource: moneycontrolAug 1st, 2019

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain.....»»

Category: marketsSource: moneycontrolDec 4th, 2017

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain - Moneycontrol.com

Closing bell: Sensex, Nifty close flat; IT, metals, PSU banks stocks gain - Moneycontrol.com.....»»

Category: topSource: googlenewsDec 4th, 2017

Market Live: Sensex, Nifty off day"s high; Infosys, Biocon, HDFC most active - Moneycontrol.com

Market Live: Sensex, Nifty off day"s high; Infosys, Biocon, HDFC most active - Moneycontrol.com.....»»

Category: topSource: googlenewsDec 4th, 2017

Market Live: Sensex gains 100 pts, Nifty hovers around 10150; Europe opens higher - Moneycontrol.com

Market Live: Sensex gains 100 pts, Nifty hovers around 10150; Europe opens higher - Moneycontrol.com.....»»

Category: topSource: googlenewsDec 4th, 2017

Market Live: Sensex gains 100 pts, Nifty hovers around 10,150; IT index up 1.5%

Market Live: Sensex gains 100 pts, Nifty hovers around 10,150; IT index up 1.5%.....»»

Category: marketsSource: moneycontrolDec 4th, 2017

Market Live: Infosys helps Sensex gain strength again; Tata Motors rises 2%

Market Live: Infosys helps Sensex gain strength again; Tata Motors rises 2%.....»»

Category: marketsSource: moneycontrolDec 4th, 2017

Market Live: Infosys helps Sensex gain strength again; Tata Motors rises 2% - Moneycontrol.com

Market Live: Infosys helps Sensex gain strength again; Tata Motors rises 2% - Moneycontrol.com.....»»

Category: topSource: googlenewsDec 4th, 2017

Market Live: Sensex off opening high, Nifty breaks 10100; Infosys, Biocon rally - Moneycontrol.com

Market Live: Sensex off opening high, Nifty breaks 10100; Infosys, Biocon rally - Moneycontrol.com.....»»

Category: topSource: googlenewsDec 4th, 2017

Market Live: Sensex off opening high, Nifty breaks 10,100; Infosys, Biocon rally

Market Live: Sensex off opening high, Nifty breaks 10,100; Infosys, Biocon rally.....»»

Category: topSource: moneycontrolDec 3rd, 2017

Biocon and Mylan"s breast cancer biosimilar receives approval from ANVISA

Biocon and Mylan"s breast cancer biosimilar receives approval from ANVISA.....»»

Category: economySource: business-standardDec 29th, 2017

Biocon hits record high on US FDA approval for generic cancer drug Ogivri

Biocon hits record high on US FDA approval for generic cancer drug Ogivri.....»»

Category: economySource: sifyDec 4th, 2017

US gives nod to Biocon-Mylan#39;s biosimilar of cancer drug Herceptin, revenues expected from FY19

US gives nod to Biocon-Mylan#39;s biosimilar of cancer drug Herceptin, revenues expected from FY19.....»»

Category: topSource: moneycontrolDec 2nd, 2017

US FDA approves Mylan-Biocon’s biosimilar for cancer drug Herceptin

US FDA approves Mylan-Biocon’s biosimilar for cancer drug Herceptin.....»»

Category: featuresSource: livemintDec 1st, 2017

Biocon gains 2% as Mylan resubmits marketing authorization applications to EMA

Biocon gains 2% as Mylan resubmits marketing authorization applications to EMA.....»»

Category: topSource: moneycontrolNov 6th, 2017

Biocon gets CRL from USFDA for anti-cancer drug

Biocon gets CRL from USFDA for anti-cancer drug.....»»

Category: topSource: moneycontrolOct 10th, 2017

Trastuzumab commercialisation on track, Biocon says after USFDA extends review deadline by 3 months

Trastuzumab commercialisation on track, Biocon says after USFDA extends review deadline by 3 months.....»»

Category: topSource: moneycontrolAug 30th, 2017

USFDA recommends approval of Biocon’s breast cancer biosimilar

USFDA recommends approval of Biocon’s breast cancer biosimilar.....»»

Category: featuresSource: livemintJul 14th, 2017

USFDA boost for Biocon: Analyst view on stock and sector

USFDA boost for Biocon: Analyst view on stock and sector.....»»

Category: topSource: moneycontrolJul 14th, 2017

ODAC’s approval takes us one step closer to USFDA nod for trastuzumab: Biocon’s CMD

ODAC’s approval takes us one step closer to USFDA nod for trastuzumab: Biocon’s CMD.....»»

Category: topSource: moneycontrolJul 14th, 2017